Psoriatic Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older (male or female)
- You have been diagnosed by a rheumatologist with one of the following conditions: rheumatoid arthritis, spondyloarthropathy (with or without inflammatory bowel disease), psoriatic arthritis (with or without active psoriasis), systemic lupus erythematosus, or Sjögren's disease
- You have given your consent to take part in the study
- You are covered by French social security (confirm with trial site)
- You are currently taking one or more of the following treatments as part of your normal care: anti-inflammatory painkillers (NSAIDs), standard pain relief medications, local or oral steroids (at a low daily dose), or certain disease-modifying or biological therapies (confirm with trial site for the full list)
Who may not be able to join:
- You received steroid treatment given directly into a vein (intravenously) less than 4 weeks ago
- You are taking oral steroid tablets at a dose higher than 15 mg per day
- You currently use CBD products or recreational cannabis, or a saliva test shows the presence of cannabis or CBD in your system
- You are currently pregnant or breastfeeding
- You are under legal guardianship or a court-appointed protection order
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Carine Pr SALLIOT, CHU Orléans
Phone: 02 38 22 99 22
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary outcome is to evaluate the biological effect of exposure of blood cells from patients suffering from IMID to different varieties of pCB extracts on the inflammatory profile.; The primary outcome is to evaluate the immunological effect of exposure of blood cells from patients suffering from IMID to different varieties of pCB extracts on the inflammatory profile.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.